TIGERMED

Tigermed opened lower and extended losses in the morning session, falling as much as 5.3% before recovering slightly in the afternoon to close at HKD 37.28, down 3.37% from the previous close of HKD 38.58, with an intraday range of approximately 4.9%. The primary catalyst was the disclosure after yesterday's close that the controlling shareholder and actual controller are under investigation. While Citi viewed the pullback as an entry point, citing unchanged fundamentals, risk aversion dominated. Q1 revenue grew 21.92% YoY to HKD 2.04 billion, but net profit slumped 68.6% YoY to HKD 55.6 million, with a net margin of only 2.72% and EPS down 66.57% to HKD 0.068. The stock trades 38.48% below its 52-week high of HKD 60.6, yet remains above its MA20 (HKD 37.106) and MA60 (HKD 34.719), with a YTD decline of 12.16%. However, the company simultaneously announced a planned A-share buyback of up to RMB 1 billion, and UBS and Daiwa have recently maintained Buy ratings, which may provide some support.

Hangzhou Tigermed Consulting saw a sharp decline in the morning session, opening at HK$39.24 and dropping to HK$37.26 by 09:49 BJ, a 5.05% fall on volume of 413,300 shares. The sell-off was triggered by Q1 2026 earnings: net profit plunged 68.62% YoY to only HK$55.6 million, with EPS falling 66.57% to HK$0.068, while revenue grew 21.92% YoY to HK$2.04 billion. Current price of HK$37.26 is 38.51% below the 52-week high of HK$60.6, though it trades above both MA20 (HK$35.11) and MA60 (HK$35.31), offering some technical support against the YTD loss of 12.21%.

Tigermed's H-shares staged a low-open rally during the morning session, surging 5.04% to HKD 40.86, reclaiming both the 20-day MA (34.89) and 60-day MA (35.44). UBS reiterated the stock as a top pick in the China CRO sector, citing solid revenue growth in 1H, while Daiwa upgraded its rating to Buy and raised the target price from HKD 35 to HKD 44, providing the key catalyst for the strong rebound. However, Q1 net profit plunged 68.62% YoY to HKD 55.6 million, with a net margin of only 2.72%, suggesting that fundamental improvement remains unconfirmed; the stock is still 32.57% below its 52-week high of HKD 60.6.

Tigermed staged a low-open rally in the morning session, rising 5.2% to HKD 39.60 as of 9:57 BJ, driven by positive research from UBS and Daiwa. UBS named Tigermed a top pick among CRO stocks, citing solid mid-term revenue growth, while Daiwa upgraded its rating to Buy though trimming the target price from HKD 52 to HKD 44. For Q1 2026, revenue grew 21.92% YoY to HKD 2.04 billion, but net profit plunged 68.62% YoY to HKD 55.6 million, with a net margin of only 2.72%, reflecting persistent profitability pressure. At HKD 39.62, the stock trades 34.6% below its 52-week high of HKD 60.6, yet has recovered above both the 20-day MA (HKD 34.46) and 60-day MA (HKD 35.49), though YTD is still down 6.6%. Sentiment, however, remains tempered by the prior investigation into major shareholders.

Tigermed staged a low-open-high-rise rally in the morning session, closing up 5.05% at HKD36.18, primarily driven by Daiwa's rating upgrade to Buy with a target price cut from HKD40 to HKD44, coupled with the company's earlier announced up to RMB1 billion A-share buyback plan. The stock bottomed at HKD33.84 before rebounding sharply to hit an intraday high of HKD36.18, recording a 6.94% intraday range. However, Q1 net profit plunged 68.62% YoY to HKD55.6 million, with EPS at only HKD0.068, while the current price remains 40.3% below the 52-week high of HKD60.6, though it sits above both MA20 (HKD33.61) and MA60 (HKD35.80), leaving the sustainability of the rebound in question.